Researchers have identified a critical role of BCL-2 in the context of cellular senescence and pulmonary fibrosis, particularly in idiopathic pulmonary fibrosis (IPF). The study highlights how conditional BCL-2 expression in PDGFRα+ fibroblasts contributes to the accumulation of senescent, pro-fibrotic fibroblasts, which resist apoptosis and perpetuate fibrotic lung remodeling. This accumulation contrasts with normal homeostatic responses where fibroblasts undergo apoptosis following injury, underscoring the pathological nature of IPF.

The findings reveal that BCL-2 not only prevents apoptosis in these fibroblasts but also drives the persistence of a fibrotic phenotype, leading to sustained lung damage. Spatial transcriptomic analysis of human IPF lung tissue corroborates the presence of senescent, BCL-2-expressing myofibroblasts specifically in fibrotic regions, providing a direct link between BCL-2 expression and the fibrotic process. Therapeutically, the study demonstrates that selective BCL-2 inhibition using ABT-199 in fibrotic mouse models can re-engage the apoptotic pathways, effectively reducing senescence and facilitating fibrosis resolution and lung regeneration.

This research positions BCL-2 as a promising therapeutic target in the treatment of pulmonary fibrosis, suggesting that interventions aimed at inhibiting BCL-2 could shift current paradigms in managing IPF. By re-establishing apoptotic pathways in fibroblasts, there is potential not only to mitigate the progression of fibrosis but also to enhance lung repair mechanisms. This work may accelerate drug development timelines for senolytic therapies, emphasizing the need for further exploration of BCL-2 inhibitors in clinical settings for patients with pulmonary fibrosis.

Source: fightaging.org